CompletedPhase 4NCT04618523
Safety and Efficacy of Recommended Antimalarial in the Democratic Republic of the Congo
Studying Malaria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ministry of Public Health, Democratic Republic of the Congo
- Principal Investigator
- Gauthier Mesia Kahunu, PhDUniversity of Kinshasa
- Intervention
- Artesunate-amodiaquine(drug)
- Enrollment
- 1117 target
- Eligibility
- All sexes
- Timeline
- 2020 – 2022
Study locations (6)
- Centre Evangélique de Coopération, Kimpese, Bas-Congo Province, Democratic Republic of the Congo
- Centre de Santé Lupidi 1, Kapolowe, Haut-Katanga, Democratic Republic of the Congo
- Centre de Santé de Référence Mikalayi, Kazumba, Kasai-Central, Democratic Republic of the Congo
- Centre de Santé de Référence Rutshuru, Rutshuru, North Kivu, Democratic Republic of the Congo
- Centre de Santé Foyer Social, Kisangani, Tshopo, Democratic Republic of the Congo
- Centre de Santé Boende 2 Nsele, Boende, Tshuapa, Democratic Republic of the Congo
Collaborators
University of Kinshasa · World Health Organization · Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04618523 on ClinicalTrials.govOther trials for Malaria
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07257965Clinical Study to Assess Minimum Mosquito Bites for P. Vivax Infection in Thai AdultsUniversity of Oxford
- RECRUITINGPHASE2NCT07147400Pfs230D1 + R21 in Matrix-M1 in African School Children and AdultsSerum Institute of India Pvt. Ltd.
- RECRUITINGPHASE2NCT07036159A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 MonthsGlaxoSmithKline
- ACTIVE NOT RECRUITINGPHASE1NCT06735209First-in-Human PfSPZ-LARC2 Vaccination/CHMINational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGPHASE2NCT07060508L9LS in Women of Childbearing Potential in MaliNational Institute of Allergy and Infectious Diseases (NIAID)
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06549257Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M AdjuvantUniversity of Oxford
- ACTIVE NOT RECRUITINGNANCT06599593Leveraging the Seasonal Malaria Chemoprevention Platform to Address Malaria and MalnutritionUniversity of California, San Francisco
- RECRUITINGPHASE4NCT07038837Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in ChadEpicentre